Founder mutation p.R1441C in the leucine-rich repeat kinase 2 gene in Belgian Parkinson's disease patients

被引:38
|
作者
Nuytemans, Karen [1 ,2 ,3 ]
Rademakers, Rosa [1 ,2 ,3 ]
Theuns, Jessie [1 ,2 ,3 ]
Pals, Philippe [2 ,3 ,4 ]
Engelborghs, Sebastiaan [3 ,5 ]
Pickut, Barbara [6 ]
de Pooter, Tim [1 ,2 ,3 ]
Peeters, Karin [1 ,2 ,3 ]
Mattheijssens, Maria [1 ,2 ,3 ]
Van den Broeck, Marleen [1 ,2 ,3 ]
Cras, Patrick [3 ,4 ]
De Deyn, Peter Paul [3 ,5 ,6 ]
van Broeckhoven, Christine [1 ,2 ,3 ]
机构
[1] Univ Antwer, Neurodegenerat Brain Dis Grp, Dept Mol Genet, CDE,VIB, B-2610 Antwerp, Belgium
[2] Inst Born Bunge, Neurogenet Lab, Antwerp, Belgium
[3] Univ Antwerp, Born Bunge Fdn, Neurobiol Lab, B-2020 Antwerp, Belgium
[4] Univ Antwerp Hosp, Div Neurol, Antwerp, Belgium
[5] Inst Born Bunge, Lab Neurochem & Behav, Antwerp, Belgium
[6] ZNA Middleheim Gen Hosp, Div Neurol, Antwerp, Belgium
关键词
Parkinson's disease; LRRK2; p.R1441C founder mutation;
D O I
10.1038/sj.ejhg.5201986
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We determined the prevalence of mutations in two major functional domains of the leucine-rich repeat kinase 2 gene (LRRK2) in Belgian Parkinson's disease (PD) patients (N = 304) of which 18.1% were familial PD patients. Ten patients were heterozygous for five different missense mutations (3.29%) of whom six carried the same mutation p. R1441C (1.97%). All six p. R1441C carriers were familial PD patients explaining 10.7% of familial PD in the Belgian patient group. Moreover, they shared a common disease haplotype of 21 consecutive markers in a region of 438 kb, suggesting that they are distant descendants of a single common ancestor. Clinically, p. R1441C carriers had typical levodopa-responsive parkinsonism with tremor as the most common presenting feature. Their age at onset was highly variable and ranged from 39 to 73 years, suggesting the influence of modifying factors. The remaining four patients were heterozygous each for a novel missense mutation located in the Roc or kinase domain. The pathogenic nature of these mutations remains to be determined, though we have genetic evidence that at least some represent rare but benign variants rather than causal mutations. The latter observation indicates that prudence is needed in diagnostic testing of LRRK2 in PD patients. Functional data should underlie a conclusion on the pathogenic nature of some mutations that have not been conclusively linked to disease.
引用
收藏
页码:471 / 479
页数:9
相关论文
共 50 条
  • [31] Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
    West, AB
    Moore, DJ
    Biskup, S
    Bugayenko, A
    Smith, WW
    Ross, CA
    Dawson, VL
    Dawson, TM
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (46) : 16842 - 16847
  • [32] A comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism
    Trinh, Joanne
    Amouri, Rim
    Duda, John E.
    Morley, James F.
    Read, Matthew
    Donald, Alan
    Vilarino-Gueell, Carles
    Thompson, Christina
    Tu, Chelsea Szu
    Gustavsson, Emil K.
    Ben Sassi, Samia
    Hentati, Emna
    Zouari, Mourad
    Farhat, Emna
    Nabli, Fatma
    Hentati, Faycel
    Farrer, Matthew J.
    NEUROBIOLOGY OF AGING, 2014, 35 (05) : 1125 - 1131
  • [33] The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation
    Rudenko, Iakov N.
    Kaganovich, Alice
    Hauser, David N.
    Beylina, Aleksandra
    Chia, Ruth
    Ding, Jinhui
    Maric, Dragan
    Jaffe, Howard
    Cookson, Mark R.
    BIOCHEMICAL JOURNAL, 2012, 446 : 99 - 111
  • [34] Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants
    Li, Xianting
    Tan, Yin-Cai
    Poulose, Shibu
    Olanow, C. Warren
    Huang, Xin-Yun
    Yue, Zhenyu
    JOURNAL OF NEUROCHEMISTRY, 2007, 103 (01) : 238 - 247
  • [35] Structure, function, and leucine-rich repeat kinase 2: On the importance of reproducibility in understanding Parkinson's disease
    Cookson, Mark R.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (30) : 8346 - 8348
  • [36] Heart Rate Variability in leucine-rich repeat kinase 2-Associated Parkinson's Disease
    Visanji, Naomi P.
    Bhudhikanok, Grace S.
    Mestre, Tiago A.
    Ghate, Taneera
    Udupa, Kaviraj
    AlDakheel, Amaal
    Connolly, Barbara S.
    Gasca-Salas, Carmen
    Kern, Drew S.
    Jain, Jennifer
    Slow, Elizabeth J.
    Faust-Socher, Achinoam
    Kim, Sam
    Valappil, Ruksana Azhu
    Kausar, Farah
    Rogaeva, Ekaterina
    Langston, J. William
    Tanner, Caroline M.
    Schule, Birgitt
    Lang, Anthony E.
    Goldman, Samuel M.
    Marras, Connie
    MOVEMENT DISORDERS, 2017, 32 (04) : 610 - 614
  • [37] The Double-Faceted Role of Leucine-Rich Repeat Kinase 2 in the Immunopathogenesis of Parkinson's Disease
    Zhang, Mengfei
    Li, Chaoyi
    Ren, Jie
    Wang, Huakun
    Yi, Fang
    Wu, Junjiao
    Tang, Yu
    FRONTIERS IN AGING NEUROSCIENCE, 2022, 14
  • [38] Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease
    Byoung Dae Lee
    Joo-Ho Shin
    Jackalina VanKampen
    Leonard Petrucelli
    Andrew B West
    Han Seok Ko
    Yun-Il Lee
    Kathleen A Maguire-Zeiss
    William J Bowers
    Howard J Federoff
    Valina L Dawson
    Ted M Dawson
    Nature Medicine, 2010, 16 : 998 - 1000
  • [39] α-Synuclein, leucine-rich repeat kinase-2, and manganese in the pathogenesis of parkinson disease
    Covy, Jason P.
    Giasson, Benoit I.
    NEUROTOXICOLOGY, 2011, 32 (05) : 622 - 629
  • [40] Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease
    Arora, Siddharth
    Visanji, Naomi P.
    Mestre, Tiago A.
    Tsanas, Athanasios
    AlDakheel, Amaal
    Connolly, Barbara S.
    Gasca-Salas, Carmen
    Kern, Drew S.
    Jain, Jennifer
    Slow, Elizabeth J.
    Faust-Socher, Achinoam
    Lang, Anthony E.
    Little, Max A.
    Marras, Connie
    JOURNAL OF PARKINSONS DISEASE, 2018, 8 (04) : 503 - 510